Table 3.
Changes in atorvastatin, losartan, and pantoprazoleatherogenicity and insulin resistance indices in males with coronary artery disease before and after consumption of RBO or SFO plus a standard diet in an 8-week randomized controlled trial
| Studied Group | P-value | ||
|---|---|---|---|
| SFO group (n = 19) | RBO group (n = 18) | ||
| Castellis risk index-I (CRI-I) | |||
| Baseline | 4.35 (1.32) | 4.61 (1.36) | 0.554 £ |
| After 8 weeks | 4.50 (1.15) | 3.42 (1.04) | 0.005 £ |
| Differences | 0.14 (1.35) | −1.19 (1.44) | 0.006 £ |
| P-value * | 0.646 | 0.003 | |
| Adjusted mean (95%CI) | 4.61 (4.14–5.08) | 3.29 (2.80–3.77) | < 0.001 δ |
| Castellis risk index-II (CRI-II) | |||
| Baseline | 2.57 (1.22) | 2.82 (1.22) | 0.529 £ |
| After 8 weeks | 2.15 (0.74) | 1.58 (0.57) | 0.014 £ |
| Differences | −0.42 (1.18) | −1.24 (1.09) | 0.035 £ |
| P-value * | 0.143 | < 0.001 | |
| Adjusted mean (95%CI) | 2.20 (1.92–2.49) | 1.52 (1.22–1.81) | 0.002 δ |
| Triglyceride to HDL-C ratio | |||
| Baseline | 1.52 (0.85) | 2.05 (0.72) | 0.046 £ |
| After 8 weeks | 1.73 (0.67) | 1.62 (0.65) | 0.604 £ |
| Differences | 0.21 (0.56) | −0.44 (0.92) | 0.013 £ |
| P-value * | 0.112 | 0.059 | |
| Adjusted mean (95%CI) | 1.86 (1.57–2.14) | 1.48 (1.18–1.77) | 0.075 δ |
| Triglyceride glucose (TyG) index | |||
| Baseline | 8.95 (0.47) | 9.36 (0.45) | 0.010 £ |
| After 8 weeks | 9.01 (0.55) | 8.87 (0.39) | 0.356 £ |
| Differences | 0.06 (0.35) | −0.49 (0.47) | < 0.001 £ |
| P-value * | 0.458 | < 0.001 | |
| Adjusted mean (95%CI) | 9.13 (8.94–9.33) | 8.73 (8.53–8.93) | 0.010 δ |
| Atherogenic coefficient (AC) | |||
| Baseline | 3.35 (1.32) | 3.61 (1.36) | 0.554 £ |
| After 8 weeks | 3.50 (1.15) | 2.42 (1.04) | 0.005 £ |
| Differences | 0.14 (1.35) | −1.19 (1.44) | 0.006 £ |
| P-value * | 0.646 | 0.003 | |
| Adjusted mean (95%CI) | 3.61 (3.14–4.08) | 2.29 (1.80–2.77) | < 0.001 δ |
| Atherogenic index of plasma (AIP) | |||
| Baseline | 0.12 (0.23) | 0.28 (0.17) | 0.019 £ |
| After 8 weeks | 0.21 (0.18) | 0.17 (0.19) | 0.582 £ |
| Differences | 0.09 (0.16) | −0.11 (0.23) | 0.005 £ |
| P-value * | 0.034 | 0.058 | |
| Adjusted mean (95%CI) | 0.24 (0.16–0.32) | 0.13 (0.05–0.21) | 0.076 δ |
| Lipoprotein combine index (LCI) | |||
| Baseline (median (IQR)) | 12.38 (18.47) | 22.32 (27.06) | 0.202 £ |
| After 8 weeks (median (IQR)) | 14.29 (8.83) | 7.01 (3.87) | 0.002 £ |
| Differences | −3.43 (14.40) | −17.40 (14.99) | 0.007 £ |
| P-value * | 0.376 | < 0.001 | |
| Adjusted mean (95%CI) | 17.53 (13.96–21.10) | 6.54 (2.86–10.21) | < 0.001 δ |
| Cholesterol index (CHOLNDEX) | |||
| Baseline | 1.57 (1.02) | 1.66 (1.06) | 0.789 £ |
| After 8 weeks | 1.16 (0.85) | 0.51 (0.57) | 0.010 £ |
| Differences | −0.41 (0.93) | −1.16 (0.90) | 0.019 £ |
| P-value * | 0.070 | < 0.001 | |
| Adjusted mean (95%CI) | 1.20 (0.90–1.50) | 0.46 (0.15–0.77) | 0.002 δ |
Data are reported as mean (standard deviation, SD) unless otherwise specified
RBO Rice bran oil, SFO Sunflower oil, HDL-C High density lipoprotein cholesterol
*Paired sample t-test or
£Independent sample t-test
δAge, baseline values, and body mass index are considered when running the analysis of covariance (ANCOVA)